Each number has its full source under its own list below.
Medicines authorised in the EU
4 medicines (authorised now). Newest first. Each links to its EMA page.
Fylrevy
Active substance: estetrol monohydrate
Lynkuet
Active substance: elinzanetant
Veoza
Active substance: fezolinetant
Puregon
Active substance: follitropin beta
Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.
Market reports on women's health
Anaemia in Women of Reproductive Age Public Health Report
Worldwide · 2024–2034
View report Public HealthAntenatal Care Coverage Public Health Report
Worldwide · 2024–2034
View report PharmaceuticalsBacterial Vaginosis Treatment
Worldwide · 2024–2034
View report Healthcare ServicesBreast Cancer Diagnostic
Worldwide · 2024–2034
View report Public HealthBreast Cancer Early Detection Public Health Report
Worldwide · 2024–2034
View report PharmaceuticalsBreast Cancer Therapeutics
Worldwide · 2024–2034
View reportFrom our blog
Women's Health Supplements: A Growing Focus
Anaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth…
Read
Breast Cancer Screening and Diagnosis: Closing the Gap
Breast cancer is the most common cancer in women worldwide. Finding it early saves lives, but access to…
Read
Fertility Services: Rising Demand and Access Gaps
About 1 in 6 adults experience infertility. In many countries one IVF cycle costs more than a year's income.
ReadEU medicine approvals on related topics
Acuitas market sizes and forecasts are only in our full reports. How we use public data.